Antibody-mediated rejection in liver transplantation: current controversies and future directions.
Interest in the role of donor-specific human leukocyte antibodies in liver transplantation has been rekindled recently. Emerging evidence suggests that these antibodies may cause injury to the liver allograft. Here we review the clinical literature, highlight controversial results, and propose a path forward for the definition and better understanding of antibody-mediated injury to the liver.
William J. von Liebig Transplantation Center, Mayo Clinic, Rochester, MN.
Timucin
T
Taner
Mark D
MD
Stegall
Julie K
JK
Heimbach
D000906:Antibodies / Q000276:immunology*; D015935:Complement C4b / Q000276:immunology; D006084:Graft Rejection; D006680:HLA Antigens / Q000276:immunology; D016027:Heart Transplantation / Q000379:methods; D006801:Humans; D007518:Isoantibodies / Q000276:immunology; D016030:Kidney Transplantation / Q000379:methods; D016031:Liver Transplantation / Q000379:methods* / Q000639:trends*; D010446:Peptide Fragments / Q000276:immunology; D014019:Tissue Donors; D014184:Transplantation, Homologous
D000906:Antibodies; D006680:HLA Antigens; D007518:Isoantibodies; D010446:Peptide Fragments; D015935:Complement C4b; C032261:complement C4d